Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide competition for antigen presentation.

L Adorini1, Z A Nagy

  • 1Preclinical Research, Sandoz Ltd, Basel, Switzerland.

Immunology Today
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Frontiers in cardiovascular medicine·2024
Same author

Worldwide forest surveys reveal forty-three new species in <i>Phytophthora</i> major Clade 2 with fundamental implications for the evolution and biogeography of the genus and global plant biosecurity.

Studies in mycology·2024
Same author

Extensive morphological and behavioural diversity among fourteen new and seven described species in <i>Phytophthora</i> Clade 10 and its evolutionary implications.

Persoonia·2024
Same author

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022
Same author

First Report of Phytophthora citricola on False Cypress in Hungary.

Plant disease·2019
Same author

First Report of Phytophthora citrophthora Causing Root and Basal Stem Rot of Woody Ornamentals in Hungary.

Plant disease·2019
Same journal

Foreword.

Immunology today·2020
Same journal

The origin and significance of anti-DNA antibodies.

Immunology today·2014
Same journal

Mutations of class II MHC molecules.

Immunology today·2014
Same journal

Antigen processing at the molecular level.

Immunology today·2014
Same journal

Phenotypically and functionally distinct T-cell subsets in anti-tumor responses.

Immunology today·2014
Same journal

Are MHC class II-restricted cytotoxic T lymphocytes important?

Immunology today·2014
See all related articles

Peptides with unrelated sequences compete for binding sites on major histocompatibility complex (MHC) molecules. This competition influences T-cell responses and offers potential therapeutic strategies for autoimmune diseases and transplant rejection.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • Major histocompatibility complex (MHC) molecules present peptide antigens to T lymphocytes.
  • MHC molecules exhibit broad peptide-binding specificity, suggesting potential for competition among different peptides.

Purpose of the Study:

  • To investigate whether peptides with unrelated sequences compete for MHC-binding sites.
  • To explore the implications of peptide competition in T-cell activation and immune responses.

Main Methods:

  • In vitro binding assays to assess peptide-MHC interactions.
  • In vivo studies in T lymphocyte models to evaluate competition and its effects.

Main Results:

  • Demonstrated in vitro and in vivo competition between peptides with unrelated sequences for MHC-binding sites.

Related Experiment Videos

  • Established that peptide competition influences the immunodominance of T-cell determinants during antigen presentation.
  • Showed that modulating peptide binding to MHC class II molecules can alter T-cell activation.

    • Conclusions:

    • Peptide competition for MHC-binding sites is a significant factor in immune regulation.
    • Interfering with peptide-MHC binding presents a potential therapeutic avenue for autoimmune diseases and allograft rejection.